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Abstract 
Interleukin-8 and its receptors are key mediators of immune and inflammatory responses. Heteronuclear NMR spectroscopy has been utilized to 
map the binding surface on interleukin-8 (IL-8) for an N-terminal fragment of the human Type-l IL-8 receptor. A peptide corresponding to residues 
140 of the IL-8 type 1 receptor (IL8-rl) was titrated into a sample of uniformly 15N-labeled IL-8. IL8-rl binds to IL-8 with a dissociation constant 
of 170 f 50 PM assuming the peptide binds wit5 a stoichiometry of one peptide per IL-8 monomer, exchanges rapidly (> 900 SK’) between free and 
bound states, and selectively perturbs the chemizd environment of several IL-8 residues. The binding surface on IL-8 suggested by our results is 
comprised of residues m strand /33 of the /I-sheet (Glu4* to Cys”), the turn preceding /_?3 (Se?), the C-terminal d-helix (Va16’) and the irregular 
N-terminal oop region (Thr”, Lys”, Phe”, His” , up” and Phe”). The IL-8 dimer appears to present two symmetrical binding surfaces for the IL8-rl 
peptide, suggesting two receptor peptides may ninci .ler dimer. 
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I. Introduction helices lying on top of a six-stranded antiparallel /?-sheet. 
Interleukin-8 (IL-X) [l] is a dimeric chemokine (1M, - 16 
kDa) released by several cell types, including monocytes, 
fibroblasts, endothelial cells, and keratmocytes, in re- 
sponse to an inflammatory stimulus [2]. In vivo and in 
vitro studies indicate that IL-8 functions in a wide range 
of proinflammatory activities, which include neutrophil 
activation [3], and the selective capacity to attract neu- 
trophils [4] and T cells [I]. IL-8 is a member of the 
cc-chemokine family of chemotactic ytokines which also 
includes platelet factor 4 (PF4), /3-thromboglobulin, y- 
interferon-induced protein, neutrophil activating protein 
2 (NAP-2) and human growth related protein (GRO) 
(also known as melanoma growth stimulating activity; 
MGSA). Structurally, members of the family share 25- 
55% sequence identity and the sequence specific place- 
ment of four conserved cysteine residues. The three di- 
mensional structures of two members of the family, IL-8 
[5,6] and PF4 [7] have been determined and share a com- 
mon polypeptide fold, consisting of two antiparallel CI- 
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Abbrevrations; GRO, growth related protein; IL-8, interleukin-8: IL8- 
rl, human type 1 IL-8 receptor 140 peptide; HSQC, heteronuclear 
single quantum coherence; MGSA, melanoma growth stimulating ac- 
tlvity; NAP-2, neutrophil activating protein 2; NMR, nuclear magnetic 
resonance; NOESY, nuclear Overhauser enhancement spectroscopy; 
PF4. platelet factor 4. 
Members of the IL-8 family modulate the activities of 
their target cells by binding to cell surface receptors. The 
amino acid sequences of two classes of IL-8 receptors 
with nearly equal affinity for IL-8 have been determined 
(Type 1 and Type 2) [8-121. The two classes are similar, 
sharing 74% sequence identity, but deviate substantially 
at their N-termini and in their ability to bind the cytokine 
GRO/MGSA and NAP-2 [12,13]. Both receptors are 
members of the rhodopsin family, receptors with seven 
membrane-spanning helices that couple to guanine nu- 
cleotide binding proteins [ 141. Recent functional studies 
indicate that peptides generated from the N-termini of 
both receptor types inhibit IL-8 binding, and only pep- 
tides derived from the type 2 receptor inhibit GROI 
MGSA binding to the intact IL-8 type 2 receptor [15]. 
Complementary mutagenesis studies of IL-8 have identi- 
fied the N-terminus (Glu4-Leu’-Arg6 and Ile”) as im- 
portant in receptor binding and cell activation [ 16,171. 
However, this is not the only structurally pertinent re- 
gion of IL-8 since GRO/MGSA contains the Glu-Leu- 
Arg sequence but inhibits IL-8 binding to Type 2 recep- 
tor only. Furthermore, IL-8 analogs shortened at the 
C-terminus show progressively reduced potency as resi- 
dues are deleted [ 181. 
In the present paper the effects of receptor binding on 
the conformation of IL-8 were investigated by heteronu- 
clear NMR spectroscopy. A fragment of the receptor, 
corresponding to residues 140 of the IL-8 type 1 recep- 
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tor (IL%rl) was titrated into a sample of uniformly “N- 
labeled IL-8. The effects of IL&r1 binding on the confor- 
mation of IL-8 were then monitored by acquisition of 
heteronuclear NMR spectra of the IL-&IL&r1 complex. 
We find that the receptor peptide binds to IL-8 with a 
dissociation constant of either 170 ? 50 PM or 340 ? 90 
,uM if the peptide binds to IL-S with a stoichiometry of 
one peptide per IL-8 monomer or one peptide per IL-8 
dimer, respectively; exchanges rapidly (> 900 s-l) be- 
tween free and bound states; and selectively perturbs the 
magnetic environment of several IL-8 residues. 
2. Materials and methods 
Recombinant IL-8 uniformly enriched with 15N was prepared as 
described previously [19,20]. A peptide comprising the N-terminal 40 
residues of human Type 1 IL-8 receptor (IL8rl) was synthesized using 
solid-phase methods and purified by reverse phase high performance 
liquid chromatography. The amino acid sequence of this peptide substi- 
tutes Ser for Cys at position 30 to prevent disulfide formation and is 
as follows: 
MSNITDPQMW”’ DFDDLNFTGM” PPADEDYSPS’” 
MLETETLNKY4” 
NMR spectra were recorded on a Bruker AMX-500 spectrometer at 
26.6”C and NMR data were processed using the in-house nmrPipe 
software (F. Delaglio, unpublished). Two-dimensional (2D) ‘H-“N 
heteronuclear single quantum coherence (HSQC) spectra [21] were ac- 
quired with 128 and 512 complex points in w, and 02, respectively. The 
3D ‘H-15N NOESY-HSQC spectrum [22,23] was acquired with 108. 38 
and 512 complex points in w,. cuZ and wj, respectively. Quadrature 
detection in the indirect dimensions of all experiments was accom- 
plished with the TPPI-States method [24]. 
The IL-8 NMR sample was 0.75 mM in monomer subunits, 50 mM 
potassium phosphate, pH 6.7, dissolved in 500 ,~l of 90% ‘HzO/lO% 
‘HZO. The ‘H-“N HSQC spectrum of unligated IL-8 was sequence 
specifically assigned using previously reported chemical shifts [19,20]. 
Lyophilized ahquots containing 0.5 mgs of IL&r1 peptide were dis- 
solved into the IL-8 sample and a ‘H-15N HSQC spectrum recorded. 
A total of four peptide additions were made resulting in final peptide 
concentrations of 0.22, 0.43. 0.65 and 0.86 mM. The final addition 
results in a IL8-rl peptide to IL-8 monomer ratio of 1.25:1. 
3. Results 
A fragment of the IL-8 receptor, corresponding to 
residues 140 of the IL-S type 1 receptor (IL8-rl) was 
titrated into a sample of uniformly 15N-labeled IL-8. 
NMR spectra of the IL8-rl peptide alone showed no 
evidence of structure. Titration of the IL8-rl peptide 
perturbed the amide ‘H and “N chemical shifts of a 
select set of IL-8 residues. Some of these IL%rl-depend- 
ent chemical shift changes are illustrated in Fig. 1, which 
shows an overlay of the ‘H-“N HSQC spectra of free 
IL-8 (solid lines) and the IL-8:IL8-rl complex (dashed 
lines) at a IL8-rl peptide to IL-8 monomer ratio of 
1.25:1. The ‘H-15N cross-peaks arising from Thr’” and 
Se? of IL-8 are substantially affected by the addition of 
peptide. In contrast, the ‘H-“N cross-peaks from Lyss4 
and Trp” are unchanged, and cross-peaks from Arg6’, 















Fig. 1. Effects of IL8-rl peptide binding on the ‘H-15N HSQC spectrum 
of IL-8. A selected region of the overlaid ‘HJ5N HSQC spectra of free 
IL-8 and the IL-8:IL8-rl complex is shown. Cross-peaks for free IL-8 
and IL-8:IL8-rl are drawn with solid and dashed lines, respectively. 
The ratio of IL8-rl peptide to IL-8 monomer is 1.25:1. 
tity of all displaced cross peaks was confirmed through 
analysis of the 3D NOESY-‘H-‘5N HSQC spectrum of 
the IL-8:IL%rl complex. 
Fig. 2 shows a plot of the chemical shift differences for 
selected residues between unligated IL-8 and the IL- 
8:IL8-rl complex as function of peptide concentration. 
The chemical shifts are perturbed as peptide is added and 
approach limiting chemical shift deviations from unli- 
gated IL-8 at saturating IL8-rl concentrations, indicat- 
ing that the perturbations are a result of IL8-rl binding 
and are unlikely to stem from changes in the solution 
conditions of the sample (i.e. pH, ionic strength, etc.). As 
a further check of this assumption the pH of the final 
IL-8:IL%rl complex (0.75 mM IL-8 monomer and 0.86 
mM IL8-rl peptide) was measured and a ‘H-“N HSQC 
spectrum of a pH matched sample of unligated IL-8 was 
recorded. The unligated spectrum did not exhibit the 
chemical shift changes of the complexed sample (data 
not shown). 
The appearance of a single set of NMR resonances 
indicates that the exchange process is fast on the NMR 
time scale. The IL-8 resonances in the presence of the 
IL8-rl peptide are the population weighted average of 
the chemical shifts of free and bound IL-S species. The 
dependence of these chemical shifts on peptide concen- 
tration therefore provides a convenient indirect measure 
of the concentration of the IL%rl:IL-8 complex. Eq. 1 
describes this dependency and was used to fit binding 
isotherms to the data by least-squares minimization 
(Fig. 2): 
dabs = dmax t (C]/]IL-81,) (1) 
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where [C] is the concentration of the IL8-rl:IL-8 com- 
plex, [IL-81, the total concentration of IL-S (either dimer 
or monomer), dabs the observed chemical shift change, 
and Amax the chemical shift difference between the IL-8 
and the IL8-rl complex. The seven curves shown in Fig. 
2 were fitted simultaneously by optimizing a single value 
for the dissociation constant and the values of Amax for 
each curve. All the experimental data could be fitted 
within experimental error and there are no systematic 
deviations between the observed and calculated curves. 
Thus all seven binding isotherms are the same. The value 
of the dissociation constants obtained is 170 ? 50 ,uM for 
a model in which two IL8-rl peptides bind per IL-8 
dimer (i.e. one IL8-rl peptide per IL-8 monomer), and 
340 & 90 ,uM for a model in which one IL8-rl peptide 
binds per IL-8 dimer. 
Plots of the “N and ‘H chemical shift differences be- 
tween the ‘H-“N HSQC spectra of unligated IL-8 and 
the IL-8:IL8-rl complex are displayed in Fig. 3A and B, 
respectively. The backbone “N chemical shifts of resi- 
dues Thr’* His ‘* Lys*‘, G1u4’, Leu4’, Cys5’ and Va16’ as 
well as the sidechain N” resonances of Q8, exhibit the 
largest displacements (Fig. 3A). The peptide dependent 
changes in the amide ‘H chemical shifts of IL-8 are less 
dramatic, with the backbone proton resonances of Lys15, 
Phe”, Phe*‘, Se?“ and Va161 exhibiting the largest pertur- 
bations (Fig. 3B). The largest 15N and ‘H chemical shift 
differences between unligated and complexed IL-8 are 
1.77 (Leu4’) and 0.3 (SerU) ppm, respectively. Hence the 
chemical exchange rate between the free and bound 
states of the peptide must exceed 900 s-l (i.e. > 27rAS 
95 
where AS is the chemical shift difference in Hz between 
the free and bound states for a system where exchange 
is fast on the chemical shift scale). 
4. Discussion 
It is possible to postulate a binding area C on IL-8 for 
the IL8-rl peptide from the observed peptide-dependent 
chemical shift changes in the resonances of IL-8. If we 
assume that the most pronounced perturbations of the 
magnetic environment of IL-8 residues occur at sites 
close to the bound peptide, resonances from those inter- 
acting residues should exhibit the largest chemical shift 
changes upon peptide binding. Fig. 4 shows a schematic 
representation of the solution structure of the IL-8 dimer 
with the Ccc atoms of residues which exhibit the largest 
“N (> IO.471 ppm) and ‘H (> IO.11 ppm) chemical shift 
changes marked with black and white spheres, respec- 
tively. These residues form a cluster on each monomer 
unit with residues from strand /33 of the B-sheet (GAUGE 
to Cys”), the turn preceding 83 (Ser”), the C-terminal 
a-helix (Va16’), and the irregular N-terminal loop region 
(Thr’*, Lys”, Phe”, His’*, Lys*O and Phe*l). Thus, the 
IL-8 dimer contains two binding areas for the peptide, 
rather than one continuous surface, suggesting that two 
peptides bind per dimer, each one sliding into the cleft 
between strand /33 and the 12-21 loop. Since the IL8-rl 
peptide is acidic (9 of 40 residues are aspartic or glutamic 
acids) basic residues of IL-8 may be involved in the 
interaction. Inspection of the region highlighted in Fig. 
0 0.2 0.4 0.6 0.6 1 
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Fig. 2. Chemical shift differences between the ‘H-“N HSQC spectra of unligated IL-8 and the IL-8:IL8-rl complex as a function of IL8-rl 
concentration. Each point results from subtracting the chemical shift of unligated IL-8 from the shifts of the IL%IL%rl complex. Residues Thr”, 
Hisi8, Se?, Leu@, CyP and Va16’ are shown. ‘HN’ and “?I’ denote proton and 15N chemical shifts, respectively. The solid lines represent non-linear 
least squares best fits to the data for simple equilibrium binding isotherms using the program FACSIMILE [26]. All seven curves were fitted 
simultaneously by optimizing the value of the maximum chemical shift change &ax for each curve and a single value for the dissociation constant. 
The dissociation constant obtained in this manner is 170 + 50 ,uM for a stoichiometry of two peptide molecules per dimer (i.e. one peptide per 
monomer) and 340 f 90 PM for a stoichiometry of one peptide per dimer. 
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4 indicates that Lys”, Lys”, Lys”, Lys4’ and Arg47 are 
plausible candidates for this. In addition, Tyri3, Phe” 
and Leu49 may be involved in hydrophobic contacts with 
the receptor. 
The peptide binding region deduced by NMR (Fig. 4) 
does not coincide with those residues identified as impor- 
tant for receptor interaction by previous mutagenesis 
studies of the IL-8 dimer [ 16,171. These studies identified 
residues Glu4 to Arg6 and Ile” of IL-8 as important in 
receptor. binding and activation [ 16,171. Resonances 
from Lys3, Glu4 and Arg’ are unresolved in the ‘H-15N 
HSQC spectra of free and complexed IL-8, preventing 
accurate analysis of their peptide dependent chemical 
shift changes. These residues, however, are probably not 
substantially affected by peptide addition, since they are 
not significantly shifted upon complexation. Further- 
more, the absence of any significant shift in the well 
resolved resonances of Ala’ and Leu5 indicates that the 
N-terminus of IL-8 which is unstructured in the free state 
[5,19], remains unstructured in the complexed form. We 
therefore believe that the N-terminal region of the IL-8 
dimer may form contacts with regions other than the 
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Fig. 3. (A) 15N and (B) ‘H chemical shift differences between the ‘H-“N 
HSQC spectra of unligated IL-8 and the IL-8:IL8-rl complex versus 
sequence number. Excluded resonances are overlapped in the ‘H-“N 
HSQC spectra. The ratio of IL8-rl peptide to IL-8 monomer is 1.25: 1 
in the complex. 
Fig. 4. Schematic ribbon diagram of the solution structure of the IL-8 
dimer. The Ca atoms of residues that exhibit the largest 15N (> IO.487 1 
ppm) and ‘H (> IO.1 1 ppm) chemical shift changes are denoted with 
black and white spheres, respectively. The figure was generated usmg 
the program MOLSCRIPT [22]. The coordmates of IL-8 are taken 
from [5] (PDB accession code lIL8). 
agenesis tudies of the IL-8 receptor support this notion, 
indicating that both the N-terminus and the third ex- 
tracellular loop of the receptor are essential determinants 
of IL-8 binding [25]. 
Although certain features of the IL-8/IL8-rl peptide 
complex seem to mimic the situation of the intact IL-8 
receptor interaction [15], it has to be stressed that our 
results should be interpreted with caution since the pep- 
tide/protein model system lacks several key features of 
the intact IL-8:IL-8 receptor system. In particular, ex- 
tracellular loops of the IL-8 receptor, N-glycosylation of 
residues at its N-terminus, a cysteine residue at position 
30, and the unique local environment present at the sur- 
face of the membrane are absent in the peptide model. 
Nevertheless, our results may provide some guidance 
with regard to mutagenesis studies on particular regions 
of IL-8. Future NMR work on IL-8 interacting with 
peptide fragments derived from other extracellular seg- 
ments of the IL-8 receptor should complement these 
studies. 
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